Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan-Mar;12(1):11-16.
doi: 10.4103/2008-322X.200161.

Comparison of Loteprednol with Fluorometholone after Myopic Photorefractive Keratectomy

Farid Karimian  1 , Amir Faramarzi  1 , Sahba Fekri  1 , Hossein Mohammad-Rabie  2 , Danial Najdi  3 , Azadeh Doozandeh  2 , Siamak Delfaza-Baher  2 , Mehdi Yaseri  4
Affiliations

Comparison of Loteprednol with Fluorometholone after Myopic Photorefractive Keratectomy

Farid Karimian et al. J Ophthalmic Vis Res. 2017 Jan-Mar.

Abstract

Purpose: To compare the efficacy and side effects of loteprednol versus fluorometholone after myopic photorefractive keratectomy (PRK).

Methods: One hundred and twenty four eyes of 62 patients who underwent PRK were enrolled in this study. One eye of each subject was randomized to receive loteprednol 0.5% and the fellow eye was given fluorometholone 0.1%. Patients were followed up for three months.

Results: There was no significant difference in uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), manifest refraction, corneal haze, intraocular pressure (IOP), and ocular discomfort and redness between groups at the final visit. At 3 months postoperatively, 20/25 or better UDVA was achieved in 95% of the loteprednol group and 92% of the fluorometholone group (P > 0.05). There was neither visually significant corneal haze nor ocular hypertension (IOP rise > 10 mmHg or IOP > 21 mmHg) in any group.

Conclusion: The efficacy and side effects of loteprednol 0.5% and fluorometholone 0.1% after myopic PRK are comparable.

Keywords: Corneal Haze; Fluorometholone; Intraocular Pressure; Loteprednol; Photorefractive Keratectomy.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

References

    1. American Academy of Ophthalmology. Excimer laser photorefractive keratectomy (PRK) for myopia and astigmatism. Ophthalmology. 1999;106:422–437. - PubMed
    1. Vetrugno M, Maino A, Quaranta GM, Cardia L. The effect of early steroid treatment after PRK on clinical and refractive outcomes. Acta Ophthalmol Scand. 2001;79:23–27. - PubMed
    1. Lane SS, Holland EJ. Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery. J Cataract Refract Surg. 2013;39:168–173. - PubMed
    1. Pleyer U, Ursell PG, Rama P. Intraocular pressure effects of common topical steroids for post-cataract inflammation: Are they all the same? Ophthalmol Ther. 2013;2:55–72. - PMC - PubMed
    1. Jung HH, Ji YS, Sung MS, Kim KK, Yoon KC. Long-Term Outcome of Treatment with Topical Corticosteroids for Severe Dry Eye Associated with Sjögren's Syndrome. Chonnam Med J. 2015;51:26–32. - PMC - PubMed